Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec Schedules Fourth Quarter and Full Year 2017 Earnings Release and Conference Call for February 27, 2018
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2017 financial results prior to market open on Tuesday,
View HTML
Toggle Summary Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full Year 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that based on preliminary unaudited financial data, the Company expects revenue for the fourth quarter of 2017 will
View HTML
Toggle Summary Oxford Immunotec to Present at the 36th Annual J.P. Morgan Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith , Chief Executive Officer, will present at the 36th Annual J.P.
View HTML
Toggle Summary Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit
Agreement includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and dismissal of all pending litigation OXFORD, United Kingdom and MARLBOROUGH, Mass. , Dec. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Ltd. (Nasdaq:OXFD) and QIAGEN N.V.
View HTML
Toggle Summary Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec to Present at the Jefferies 2017 London Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Reports Third Quarter 2017 Financial Results
Third quarter revenue of $30.4 million, an increase of 17% compared to prior year period Continued growth from both the Tuberculosis (TB) and Tick-borne disease franchises, with double-digit revenue growth in all three geographies served Gross margin improved by 450 basis points on a sequential
View HTML
Toggle Summary Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Announces Update in Patent Infringement Litigation
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec to Present at the Baird 2017 Global Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) --  Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML